Cardiovascular HealthAdvanced Lipid Panel
NMR LipoProfile: Advanced Lipid Testing Guide
Go beyond the standard lipid panel with NMR LipoProfile — LDL particle number, particle size, LP-IR score, ApoB, and Lp(a). The advanced cardiovascular risk markers that matter.
Sample: Fasting Blood•Clinical reference guide
Overview
The NMR LipoProfile uses nuclear magnetic resonance spectroscopy to directly measure lipoprotein particle number, size, and concentration. This goes far beyond the standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) to provide a more accurate assessment of cardiovascular risk. The key insight: LDL particle number (LDL-P) is a more precise indicator of cardiovascular risk than LDL cholesterol concentration (LDL-C).
Why Standard Lipid Panels Are Insufficient
Standard lipid panels measure cholesterol content carried by lipoproteins, not the number of particles. This creates a critical gap:
- A patient with "normal" LDL-C may have a high number of small, dense LDL particles (high risk)
- A patient with "high" LDL-C may have large, buoyant LDL particles (lower risk)
- Up to 50% of heart attacks occur in people with "normal" cholesterol
When to Order
- Family history of premature cardiovascular disease
- Metabolic syndrome or insulin resistance
- Type 2 diabetes
- Discordance between standard lipid panel and clinical presentation
- Patients on statin therapy needing better risk stratification
- Unexplained elevated LDL-C
- Assessment of residual cardiovascular risk
- Monitoring response to dietary/lifestyle interventions
Key Biomarkers
NMR LipoProfile Markers
| Marker | What It Measures | Clinical Significance |
|---|---|---|
| LDL-P (LDL Particle Number) | Total count of LDL particles | PRIMARY risk marker. HIGH = higher CV risk regardless of LDL-C. Functional optimal: <1000 nmol/L |
| Small LDL-P | Number of small, dense LDL particles | Small dense LDL is more atherogenic — penetrates arterial walls more easily, oxidizes more readily. Functional optimal: <527 nmol/L |
| LDL Size | Average LDL particle diameter | Pattern A (large/buoyant) = lower risk. Pattern B (small/dense) = higher risk. Cutoff: 20.5 nm |
| HDL-P (HDL Particle Number) | Total count of HDL particles | Higher = more protective. Functional optimal: >30.5 μmol/L |
| Large HDL-P | Number of large HDL particles | Large HDL most effective at reverse cholesterol transport |
| HDL Size | Average HDL particle diameter | Larger = more functional |
| Large VLDL-P | Number of large VLDL particles | Reflects triglyceride metabolism. HIGH = insulin resistance |
| VLDL Size | Average VLDL diameter | Larger VLDL correlates with metabolic dysfunction |
| LP-IR Score | Lipoprotein Insulin Resistance Score | 0-100 scale. Composite score predicting insulin resistance. >45 suggests insulin resistance. Combines VLDL, LDL, and HDL particle data |
LipoMap (Boston Heart) — 33-Part Analysis
Uses 600 MHz NMR for more detailed particle measurement including specific lipids, apolipoproteins, and lipoprotein particles.
Additional Advanced Lipid Markers (from various panels)
| Marker | What It Measures | Clinical Significance |
|---|---|---|
| Apolipoprotein B (ApoB) | One ApoB per atherogenic particle | Direct measure of atherogenic particle number. Functional optimal: <80 mg/dL. Some consider ApoB the single best CV risk marker |
| Lipoprotein(a) [Lp(a)] | Genetically determined lipoprotein | HIGH = independent CV risk factor. >50 nmol/L = elevated risk. Largely genetic — not modifiable by lifestyle |
| Remnant Cholesterol | Cholesterol in remnant particles | Emerging risk factor — atherogenic |
| Oxidized LDL | LDL that has been oxidized | Direct measure of oxidative damage to LDL — highly atherogenic |
| hs-CRP | Systemic inflammation | When combined with lipid data, improves risk prediction. Functional optimal: <1.0 mg/L |
Functional Medicine Interpretation Framework
Risk Stratification
| Category | LDL-P | Small LDL-P | LP-IR | Interpretation |
|---|---|---|---|---|
| Low Risk | <1000 | <527 | <25 | Optimal lipoprotein profile |
| Moderate Risk | 1000-1299 | 528-1000 | 25-44 | Monitor, lifestyle intervention |
| High Risk | 1300-1599 | >1000 | 45-75 | Aggressive intervention needed |
| Very High Risk | ≥1600 | >1000 | >75 | High atherogenic burden + insulin resistance |
Pattern Recognition
-
Metabolic Syndrome Pattern:
- High large VLDL-P + Small dense LDL + Low large HDL-P + High LP-IR
- Address insulin resistance FIRST (this drives the entire pattern)
-
Discordant LDL-C vs LDL-P:
- Normal LDL-C but HIGH LDL-P = "hidden risk" — treat as high risk
- High LDL-C but LOW LDL-P = lower risk than LDL-C suggests (large buoyant particles)
-
Familial Hyperlipidemia:
- Very high LDL-P with large particles = likely genetic (FH)
- Check Lp(a), consider genetic testing
-
Insulin Resistance Pattern:
- LP-IR >45 + elevated triglycerides + low HDL-C
- This pattern often normalizes with carbohydrate restriction and exercise before lipids change
Cross-References to Standard Blood Labs
| NMR Finding | Cross-Reference With |
|---|---|
| High LP-IR score | Fasting insulin, HOMA-IR, HbA1c, fasting glucose |
| High small LDL-P | Triglyceride/HDL ratio (>3 suggests small dense pattern) |
| High Lp(a) | APOE genetic testing, homocysteine |
| High hs-CRP with lipid abnormalities | Full inflammatory panel (fibrinogen, IL-6, ferritin) |
| Metabolic syndrome pattern | Metabolic panel, fasting insulin, uric acid, GGT |
| High ApoB | Standard lipid panel for comparison |
Cross-References to Other Specialty Tests
- DUTCH test: Cortisol dysregulation affects lipid metabolism
- GI-MAP: Gut dysbiosis affects bile acid metabolism and cholesterol clearance
- Genetic panels: APOE genotype affects LDL metabolism (E4 = higher LDL, E2 = lower)
- NutrEval: Fatty acid balance affects lipid profile
- Thyroid panel: Hypothyroidism elevates LDL
Clinical Pearls
- LDL-P > LDL-C: When they disagree, LDL-P is the better predictor of cardiovascular events
- LP-IR is predictive: Identifies insulin resistance 5-10 years before fasting glucose becomes abnormal
- Particle size matters: Small dense LDL is 3-7x more atherogenic than large buoyant LDL
- Triglyceride/HDL ratio as proxy: TG/HDL ratio >3.0 suggests small dense LDL pattern even without NMR
- ApoB as single best marker: Some cardiologists consider ApoB the single most informative cardiovascular marker
- Lp(a) is genetic: Test once in a lifetime. If elevated, aggressive management of other modifiable risk factors
- Diet affects particle size rapidly: Low-carb/Mediterranean diet shifts pattern B → pattern A within weeks
- Fasting required: 10-12 hour fast for accurate results
Metabolic Health Bootcamp Integration
From the Casey Means metabolic testing bootcamp content:
- Biomarkers included in metabolic panel: CBC w/ Diff, HbA1c, ApoB, Triglycerides, HDL Cholesterol, CMP, Insulin, CRP, GGT, Uric Acid, Vitamin D
- Key insight: Metabolic dysfunction is the root cause of most chronic disease; lipid testing should always be contextualized with metabolic markers (insulin, glucose, HbA1c, uric acid)
- CGM integration: Continuous glucose monitoring paired with advanced lipid testing provides the most comprehensive metabolic assessment
NMR LipoProfileLDL-PApoBLp(a)particle sizecardiovascular riskadvanced lipids
Related Tests & Panels
Related Blog Posts
Get Your Labs Analyzed
Lab Sage uses functional medicine optimal ranges to decode your lab results — going beyond conventional "normal" to show you what optimal health looks like.